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Background: While the European Union is striving to become the ‘Innovation Union’, there remains a lack of quantifiable
indicators to compare and benchmark regional innovation clusters. To address this issue, a HealthTIES
(Healthcare, Technology and Innovation for Economic Success) consortium was funded by the European
Union’s Regions of Knowledge initiative, research and innovation funding programme FP7. HealthTIES
examined whether the health technology innovation cycle was functioning differently in five European
regional innovation clusters and proposed regional and joint actions to improve their performance. The
clusters included BioCat (Barcelona, Catalonia, Spain), Medical Delta (Leiden, Rotterdam and Delft, South
Holland, Netherlands), Oxford and Thames Valley (United Kingdom), Life Science Zürich (Switzerland), and
Innova Észak-Alföld (Debrecen, Hungary).
Methods: Appreciation of the ‘triple helix’ of university–industry–government innovation provided the
impetus for the development of two quantifiable innovation indexes and related indicators. The HealthTIES H-index is
calculated for disease and technology platforms based on the h-index proposed by Hirsch. The HealthTIES Innovation
Index is calculated for regions based on 32 relevant quantitative and discriminative indicators grouped into 12
categories and 3 innovation phases, namely ‘Input’ (n = 12), ‘Innovation System’ (n = 9) and ‘Output’ (n = 11).
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Results: The HealthTIES regions had developed relatively similar disease and technology platform profiles, yet with
distinctive strengths and weaknesses. The regional profiles of the innovation cycle in each of the three phases were
surprisingly divergent. Comparative assessments based on the indicators and indexes helped identify and share best
practice and inform regional and joint action plans to strengthen the competitiveness of the HealthTIES regions.
Conclusion: The HealthTIES indicators and indexes provide useful practical tools for the measurement and benchmarking
of university–industry–government innovation in European medical and life science clusters. They are validated internally
within the HealthTIES consortium and appear to have a degree of external prima facie validity. Potentially, the tools and
accompanying analyses can be used beyond the HealthTIES consortium to inform other regional governments, researchers
and, possibly, large companies searching for their next location, analyse and benchmark ‘triple helix’ dynamics within their
own networks over time, and to develop integrated public–private and cross-regional research and innovation strategies in
Europe and beyond.
Keywords: Regional innovation cluster, innovation index, triple helix, university–industry–government innovation, Regions of
Knowledge, life sciences, medical sciences, biotechnology, public policy, European UnionBackground
As policy-makers see innovation as a key driver of eco-
nomic growth and wealth creation, the European Union
(EU) is striving to become the ‘Innovation Union’ [1].
Despite substantial policy focus and investment in re-
search and innovation at the regional level, comparing
and benchmarking European regional innovation clus-
ters is still in its formative stage and remains limited in
scope. Benchmarking usually takes the form of observa-
tional studies of national innovation systems, sometimes
with extended regional scoreboards. For example, the
Regional Innovation Scoreboard was developed as an ex-
tension of the Innovation Union Scoreboard to measure
the innovation performance of European regions on a
limited number of indicators [2–4]. The Regional Eco-
system Scoreboard places emphasis on the dynamics and
conditions that characterise the quality and nature of
innovation and entrepreneurship in administrative re-
gions, defined according to the Classification of Territor-
ial Units for Statistics (NUTS) nomenclature of
territorial units for statistical purposes [5]. The Cluster
Observatory provides a range of macro- and
micro-economic mapping data, reports on clusters and
regional competitiveness conditions, information about
cluster organisations, as well as educational resources
[6]. In addition, a number of EU commissioned reports
highlight the varied quantification of the different phases
of the innovation cycle, and the identification of critical
factors that stimulate clustering from both a ‘bottom-up’
and ‘top-down’ perspective [7, 8]. The primary objective
of such scorecards and reports are the relative ranking
of countries and large administratively defined regions,
but they do not necessarily capture the workings and
competitive advantages of actual innovation clusters
from a regional co-ordination perspective [9, 10]. More-
over, it remains unlikely that they are sensitive to varia-
tions between industry sectors, and therefore objectiveand quantifiable data tailored to the biotech, medical
technology and pharma sectors are required for effective
benchmarking and time dependent analysis [7, 11].
Herein, we focus on actual regional innovation clus-
ters, defined as a critical mass of research innovation in
academic institutions and companies that are located
within a relatively small geographic area [12, 13]. Geo-
graphic clustering allows companies to derive competi-
tive advantage, not only from their own resources and
capabilities, but also from the shared resources and cap-
abilities located in their geographical proximity [14].
Such geographic clustering is considered to encourage
cross-sector networks, spin-out companies, investment,
collaborations and regional development, particularly
when there is a strong presence of innovative firms from
the same industry [15]. Interactions between large com-
panies, small- to medium-sized enterprises and research
organisations that lead to the sharing and exchange of
facilities, knowledge and people, are likely to contribute
to technology transfer. Importantly, these interactions
may be catalysed through extended networking,
personnel and information dissemination within and be-
tween clusters [9]. Regions that have developed such
clusters, especially those with a strong presence of uni-
versities and knowledge-based industry, are considered
to have enhanced economic competitiveness, innovation
and growth [16]. Given the benefits of clustering, na-
tional governments, the European Commission and
intergovernmental organisations such as the OECD, ad-
vocate creating regional clusters, particularly in the areas
that maximise public good [16–21]. The ‘triple helix’ of
university–industry–government relations to increase
the potential for innovation and wealth creation is now
developed through new organisations such as science
parks and incubators that cut across the university–in-
dustry–government boundaries. Thus, quantitative
benchmarking of regional clusters is an essential
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accelerate the impact of regional medical and life science
clusters on health and wealth creation.
In the field of science, technology and innovation
(STI) studies, there are six established sources of data
and related approaches [22] that can be potentially used
to quantify and measure innovation with a high degree
of comparability across a number of diverse regions.
First, national-level research and development (R&D)
data are used to characterise national contexts and in-
puts into the innovation process as well as innovation
activities [23]. Second, patents and citations provide in-
sights into the invention process [24–27]. Third, biblio-
metrics help understand and forecast the scientific
process underpinning inventions [28, 29]. Fourth, tech-
nometrics rely on expert opinion to assess technological
change and its policy implications [30, 31]. Fifth,
topic-specific databases and innovation surveys provide
statistics on collaboration, commercialisation, financing
and other innovation activities and opportunities [32–
34]. Finally, composite synthetic indicators use a variety
of data sources to assess innovation capabilities and per-
formance [35, 36].
Building on the established STI approaches, we report
and discuss methods and results pertaining to the devel-
opment of new HealthTIES (Healthcare, Technology and
Innovation for Economic Success) indicators and in-
dexes for benchmarking university–industry–govern-
ment innovation in European medical and life science
clusters. The HealthTIES project was part of the €126
million (2007–2013) Regions of Knowledge initiative
supported by the European Commission under the re-
search and innovation funding programme FP7 [37].
The aim of the initiative was “to support trans-national
mutual learning and cooperation between research-
driven clusters, bringing together regional authorities and
development agencies, public research organisations, in-
dustry and other relevant stakeholders” [37]. The main
activities developed by HealthTIES to achieve the aims
of Regions of Knowledge were to complete a detailed set
of quantitative assessments for the analysis of regional
clusters, including the development of a ‘virtual refer-
ence cluster’, to develop a mentoring strategy between a
highly developed cluster (Life Science Zürich) with one
less developed (Debrecen, Hungary), and to develop a
set of regional action plans to improve the integration of
contributors to regional economies.
Given that the primary focus of our project was on the
HealthTIES regions, we initially disseminated and used
the results of the project to inform actions within the re-
gions. Yet, there are a paucity of such research outputs
from this and other projects in the public domain and
peer-reviewed literature [38], similar to what is observed
for other European-funded projects and initiatives. Arecent study in Health Research Policy and Systems
demonstrated that, although significant public resources
are invested in European-funded health projects, data
and reports from such projects are often unavailable or
inaccessible [39]. Globally, billions of dollars in research
investment are wasted when full information about
health research studies is inaccessible [40]. In line with
the objectives of Responsible Research and Innovation
[41], which increases the value of European research in-
vestment, we herein make the results from the Health-
TIES project publicly available in Open Access format.
Methods
Aim and objectives
We established the HealthTIES consortium [42] to de-
liver on the stated aim of the Regions of Knowledge by
examining whether the health technology innovation
cycle was functioning differently in five European re-
gional innovation clusters, and to propose regional and
joint actions to improve their performance. The specific
objectives were as follows:
 develop indicators and indexes for assessing
knowledge and innovation capital and the
functioning of the innovation cycle;
 identify key stakeholders and collect data to
operationalise the proposed indicators and indexes;
 propose joint and regional actions to improve
regional performance through benchmarking and
mutual learning.
Study setting
The HealthTIES consortium consisted of five European
regional clusters centred around the following cities
(Fig. 1):
 Barcelona (Bioregion of Catalonia, Catalonia),
 Leiden, Rotterdam, and Delft (Medical Delta, South
Holland),
 Oxford (Oxford and Thames Valley, United
Kingdom),
 Zürich (Life Science Zürich, Switzerland),
 Debrecen (Innova Észak-Alföld, Hungary).
We selected the first four participating clusters on the
basis of pre-existing bilateral collaboration between clus-
ter members and their proven track record in medical
and life sciences research and innovation [38]. Innova
Észak-Alföld was selected as a mentoring cluster on the
basis of its potential to accelerate research-driven
innovation. Hungary has one of the most developed bio-
technology sectors among the new EU member states,
and Debrecen had attracted significant investments from
Gedeon Richter Plc. to build a new biotechnology
Fig. 1 The HealthTIES (Healthcare, Technology and Innovation for Economic Success) consortium
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ope [43].
Theoretical framework
To guide data collection, analysis and actions, this study
used the established ‘triple helix’ model of university–in-
dustry–government relations based on the theoretical
insight that universities, industry and government are be-
coming increasingly interdependent and co-evolving, while
retaining their institutional identities [17, 21, 44–46]. Im-
perative to the functioning of the ‘triple helix’ is the cre-
ation of the ‘knowledge space’ to intensify research andgenerate new knowledge through collaboration, the ‘con-
sensus space’ to build relationships, agree on objectives and
develop joint actions, and the ‘innovation space’ to imple-
ment joint actions by bringing together knowledge, busi-
ness expertise and venture capital. The ‘new organisational
actors’ or ‘hybrid organisations’, such as science parks, incu-
bators and new forms of venture capital, which span trad-
itional university–industry–government boundaries, are
shown to be effective in creating the aforementioned
‘spaces’ [21, 47, 48].
Under the assumptions of ‘triple helix’ model, maxi-
mising interactions, creating ‘spaces’ and new
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government boundaries are proposed to increase the po-
tential for innovation and wealth creation through free
movement of people, knowledge and venture capital be-
tween universities, industry and government.
Data collection and analysis
For each cluster, we collected and analysed the most re-
cent data pertaining to universities, industry, govern-
ment and new boundary-spanning organisations during
the lifespan of the project (2010–2013). Most of our
cross-sectional data and analyses refer to 2010 or 2012.
We used a variety of well-established STI sources of data
and approaches to data analysis. Namely, we collected
and analysed R&D data from statistical offices and insti-
tutions, bibliometric data, public and commercial data-
bases, and a number of readily available composite
synthetic indicators. These data and analyses formed the
basis of the HealthTIES H-index for disease and technol-
ogy platforms and the HealthTIES Innovation index fo-
cusing on four disease fields (cardiovascular disease,
cancer, neurodegenerative disease, immunology and in-
fectious disease) and three technology platforms (mo-
lecular technology, imaging, and drug design,
development and delivery).
We selected these disease fields and technology plat-
forms on the basis of the concurrent assessment of the
burden of mortality and morbidity in Europe as well as
scientific and technological change and by the project’s
experts as the most promising for improving the health
of European citizens and making European health sys-
tems more sustainable in the context of the increasingly
ageing population. Cardiovascular disease, cancer, infec-
tious diseases and neurodegenerative diseases are the
leading causes of mortality and morbidity in Europe.
Frequently, they are manifestations of patient/gene–en-
vironment interactions. Therefore, interventions directed
at environmental risk factors, such as alcohol, obesity
and tobacco, are likely to have important but mixed ben-
efits depending upon underlying genetic factors and age
at exposure. Recent scientific and technological break-
throughs in molecular technology and imaging, as well
as drug design, development and delivery have opened
up new opportunities for primary prevention of these
diseases through risk factor identification and secondary
prevention through early and accurate diagnosis, as well
as more appropriate and effective treatments.
HealthTIES H-index for disease and technology platforms
To assess the knowledge and innovation capital in each
region we used bibliometric h-indexes [49]. Although
most commonly h-indexes are calculated for individual
researchers, they could also be calculated for regions,
diseases and technologies. We calculated h-indexesusing the Clarivate Web of Science, formerly Web of
Knowledge, research platform (www.webofknowledge.-
com) to benchmark our regions in four relevant disease
fields and three technology platforms. Our protocol and
search terms are shown in Additional file 1: Box S1 and
Table S1, respectively. The HealthTIES h-index (HT
H-index) for publications in a region in a specific field
specifies the number HT of scientific articles for a given
keyword (i.e. cardiovascular) for a given address (e.g.
Zürich) that have been cited in other articles at least HT
times according to Hirsch [49]. As the h-index depends
on the length of a person’s scientific career, the HT
H-index depends on the volume of research activity
within clusters. The HT H-index permits the compari-
son of the relative strengths of a given location for spe-
cific keyword search terms and thus offers a valuable
assessment of the research output of a cluster in a given
disease or technology platform.
HealthTIES innovation index
In an effort to create a ‘consensus space’ for building re-
lationships, agreeing on objectives and developing joint
actions under the assumptions of the ‘triple helix’ model,
each cluster assembled a regional team, including repre-
sentatives from small- to medium-sized enterprises, bio-
tech parks, local government, hospitals, technology
transfer offices (TTOs) and academia. Initially, we col-
lected a wide range of data for each region, but it be-
came clear that these data were either not necessarily
available for each region, or were not comparable, or
were not quantifiable. A workshop was convened to dis-
cuss the best data to collect and how to apply this to an
index. All regional clusters were represented by 15
members, extending across every strand of the ‘triple
helix’. We had discussions about the significance, valid-
ity, reliability and feasibility of the potential indicators
facilitated by an independent consultant, and we reached
consensus on which indicators to select. As a result, we
developed a logic model of the innovation cycle consist-
ing of three key phases, namely input, innovation system
activity and outputs (Fig. 2).
We then compiled a list of potential indicators for
each phase of the innovation cycle excluding those indi-
cators for which no information was available or would
not be feasible to collect. This process resulted in 32
quantitative indicators, which were grouped into 12 cat-
egories and three phases of the innovation cycle, namely
‘Input’ (n = 12), ‘Innovation System’ (n = 9) and ‘Output’
(n = 11) (Table 1). We also assigned, to each indicator, a
weighting factor reflecting the relative significance of the
underlying component in the innovation cycle. We de-
termined mean scores for each weighting factor by vot-
ing among the 15 members present at the meeting,
followed by wider circulation to all the members of the
Fig. 2 A logic model of the HealthTIES (Healthcare, Technology and Innovation for Economic Success) innovation cycle with key indicator categories
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feedback, amendments and endorsement of the final set
of indicators and weighting factors (Table 1).
Input indicators
The final set includes 12 indicators to measure inputs in
four categories. First, the numbers of highly cited profes-
sors and publications were deemed to be proxy indica-
tors for the depth and breadth of the current scientific
knowledge base. Given that the h-index reflects the dur-
ation of one’s scientific career, an h-index > 30 was
chosen as a threshold for highly cited professors to also
include younger researchers who had already made a
significant impact on their respective fields. Second, the
scope of the current research activity was measured
through research funding. In doing so, currencies other
than the euro were converted into euros using historical
exchange rates. Third, both quantity and quality of hu-
man capital were considered to be central to current
and future discoveries and innovation. We measured the
numbers of graduated national and international MSc
and PhD students as well as the numbers of European
Research Council junior and advanced grants, which
serve as a pan-European mark of research quality.
Fourth, to approximate research infrastructure for
current and future research, we measured research
space, research hospital beds, and Phase I and II clinicaltrials. The latter indicate activity levels in proof of con-
cept drug development.
Innovation system indicators
There are nine indicators to measure innovation system
activity in three categories. First, the existing levels of
innovation that were deemed to be reflected in intellec-
tual property, university–industry technology transfer
and adoption of innovation. Intellectual property and
university–industry technology transfer were measured
by the numbers of university spin-off companies,
granted United States patents, and the number of uni-
versity–industry collaborations larger than 5 million
euros. The patients WAIT indicator (patients Waiting
for Access to Innovative Treatment) was used to meas-
ure how fast innovations and new drugs are made avail-
able to the public [50]. Second, support for innovation
was measured by the number of full-time equivalent
(FTEs) posts in university TTOs in a given region and
the extent of national government procurement of ad-
vanced technology. Third, the quality of innovation in-
frastructure was deemed to be reflected within the
regional science park capacity and the overall national
attractiveness. The capacity of regional science parks
was measured by the size of space available in square
meters and by the number of support staff in FTEs. The
national attractiveness was deemed to be reflected by
Table 1 HealthTIES innovation indicators, data sources and weighting factors
Innovation
phase
Category Code Indicator General data source Weighting
factor
Input Scientific
knowledge
A01 Profs h-index > 30 University index of profs, Web of Science 18
A02 Publications 2001–2010 Web of Science 16
Research
funding
A03 Research funding Research institutions: annual reports, support staff 24
Human capital A04 International graduated MSc students Research institutions: annual reports, support staff 3
A05 International PhD students Research institutions: annual reports, support staff 3
A06 National graduated MSc students Research institutions: annual reports, support staff 3
A07 National PhD students Research institutions: annual reports, support staff 3
A08 Junior ERC grants 2007–2010 Lists of ERC-funded starting grants 8
A09 Senior ERC grants 2008–2010 Lists of ERC-funded advanced grants 8
Research
infrastructure
A10 Research space m2 Research institutions: Facility managing staff 3
A11 Research hospital beds Websites and support staff of hospitals 3
A12 Clinical trials phase I and II ClinicalTrials.gov database 8
Innovation
System
Intellectual
property
B01 University spin-offs 2007–2010 TTO staff 17
B02 Granted US patents 2007–2010 See-the-Forest Patent Analytics by IP Vision 14
Innovation
adoption
B03 WAIT indicator for countries EFPIA Patients WAIT indicator 11
Technology
transfer
B04 University–industry research collaborations
> €5 M
TTO/support staff of research institutions, EU
project database Cordis
11
Support B05 TTO staff FTEs TTO staff 13
B06 National government procurement of
advanced technology
WEF GCR 2010–2011, pillar 12.05 11
Infrastructure B07 National attractiveness (WEF index) WEF GCR 2010–2011 12
B08 Science parks m2 Science parks 6
B09 Science park staff FTEs Science parks 5
Output Biotech jobs C01 Jobs in biotech companies FTEs Chambers of commerce, statistical offices 21.5
Biotech
companies
C02 Biotech companies < 20 FTEs Chambers of commerce, statistical offices 5
C03 Biotech companies > 20 FTEs Chambers of commerce, statistical offices 10.5
Big trade sales C04 Big trade sales > €100 M 2001–10 Regional experts 5.5
Products C05 Products on market BiotechGate database 11
C06 Products in clinical trials BiotechGate database 10
C07 Products in discovery phase BiotechGate database 5.5
C08 Medicines available in countries EFPIA Patient’s WAIT indicator 7
Capital C09 Total investments 2007–2010 BiotechGate database 8
C10 Number of investments 2007–2010 BiotechGate database 8
C11 Average Series A investments 2007–2010 BiotechGate database 8
EFPIA European Federation of Pharmaceutical Industries and Associations, ERC European Research Council, FTE full-time equivalent, GCR Global Competitiveness
Report, TTO technology transfer office, WAIT Waiting to Access Innovative Therapies, WEF World Economic Forum
Edmunds et al. Health Research Policy and Systems           (2019) 17:10 Page 7 of 15the World Economic Forum Global Competitiveness
index [51].
Output indicators
There were 11 indicators to measure direct and more
immediate outputs of the innovation system in five cat-
egories. First, the number of jobs in biotech companies
was deemed to be one of the key indicators foreconomic growth and wealth creation. Second, we mea-
sured the number of non-subsidiary independent biotech
companies, distinguishing between smaller companies
(with fewer than 20 FTE employees) and larger compan-
ies (with 20 or more employees). Third, we measured
the number of big trade sales (larger than 100 million
euros), where small companies financed by venture cap-
ital or private equity were bought up by large life
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ies. Fourth, we measured the number of regional biotech
companies’ products and the total number of medicines
available nationally. The number of regional biotech
companies’ products included those on the market, in
clinical trials phases I–III and awaiting United States
Food and Drug Administration approval, and in the
pipeline, including discovery and lead optimisation. Fi-
nally, we measured capital as reflected in the total
amount of investments (in euros), number of invest-
ments and the value of average Series A investments, i.e.
the first significant venture capital investments. Given
that there was no common publicly available data source
for all of the HealthTIES regions, we operationalised
products and capital indicators using the BiotechGate
database (www.biotechgate.com) established by Venture
Valuation Ltd., located in Zürich. BiotechGate is the lar-
gest life science company database in Europe and the
United States, established primarily for the purposes of
supporting partnering meetings. They allowed us to
search our specific regions in their BiotechGate database
(www.biotechgate.com). Although it is the most compre-
hensive database that is currently available, it is not ex-
haustive and is dependent on voluntary registration.
Therefore, comparison of the indicators derived from
this database may have known limitations.
Comparison and benchmarking
All indicator data were converted into points, on linear
scales ranging from 0 to 10, with 10 being the highest
aspirational score. The highest actual data value of an in-
dicator in any HealthTIES region was set at 7.5 points.
This implied that each region may improve to 10 points
in the future. This presentation method was applied to
both HT Innovation and H-indexes. As stated, each HT
Innovation indicator was then attributed by the Health-
TIES consortium consensus, a relative weighting factor
(Table 1). Overall scores were calculated by multiplying
indicator points by the corresponding weighting factors.
Category scores were obtained by adding up indicator
scores within a category. Radar plots were used to visu-
alise and compare indicator and category scores. The
original benchmarking results for 2010 and 2012 are re-
ported below and in Additional file 1.
Results
Comparative assessment of the knowledge and
innovation capital
Selection of common bibliometric indicators enabled the
comparison of the knowledge and innovation capital in
regional clusters across operationally independent dis-
ease and technology platforms (Fig. 3). Strikingly, all
four advanced regions had developed a relatively similar
shape of disease and technology platform profiles, yetwith distinctive strengths and weaknesses. For example,
the strength of microscopy in Zürich and its weakness in
Barcelona (Bioregion of Catalonia; BioCat), or the
strength of clinical trials in Oxford and Medical Delta
and their weakness in Zürich.
We also compared the average HealthTIES disease and
technology platform profile with the profile of Boston,
which is a renowned metropolitan area in life science
innovation [52]. We found that the shape of disease and
technology platform profiles was similar, but of signifi-
cantly greater magnitude in Boston (Fig. 3). The relative
similarity of regional profiles across Europe, especially
with respect to cancer and cardiovascular disease, is
likely to reflect the relatively similar priorities for health-
care funders. By contrast, the relatively limited activity
in the public domain in chemistry and drug develop-
ment is likely to reflect the concentration of this activity
in the pharmaceutical industry.Comparative assessment of the innovation cycle using the
HealthTIES Innovation Index
The profiles obtained for each regional cluster in each of
the three phases of the innovation ecosystem were sur-
prisingly divergent (Fig. 4 and Additional file 1: Figure
S1–S5). Thus, with a single time point or snapshot, it
was difficult to determine the exact cause and effect re-
lationships between indicators. This could also suggest
that no one uniform template for regional innovation
clusters exists in Europe, and that variation may be re-
gional and context dependent.
In support of the utility of the HT Innovation index
over time, the changes in data over two periods was de-
termined in two regions where we could reassess all in-
dicators (Additional file 1: Figure S6). These data
strongly suggest that there is a time-dependent dynamic
of the investment, innovation and outputs along the
innovation cycle, illustrating the need for temporal as-
sessments to evaluate fluctuations and (in)stability of the
cluster. Over a given time, Life Science Zürich developed
both investment and products on the market, whereas
Oxford and Thames Valley and Medical Delta have
achieved major increases in investment, but with little
change in product or outputs in this period. Yet, Oxford
and Thames Valley have a number of products in devel-
opment, and this probably reflects an emphasis on clin-
ical trials. Without a quantifiable HT Innovation index
with temporal evaluation, there is a risk that these data
could be misinterpreted. For example, the effect of in-
creasing external investment in one particular area may
not have impact on wealth creation. Likewise, increasing
forward intellectual property without correlated develop-
ment of investment may not translate to potential im-
pacts on healthcare outcomes.
Fig. 3 A comparative assessment of the knowledge and innovation capital using the HealthTIES H-index for disease and technology platforms,
2010. Data are expressed relative to a maximum of 7.5 in the best performing HealthTIES region
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The indexes were then used to identify the relative
strengths, weaknesses and opportunities in each cluster to
benchmark regions, and provide a set of common
innovation indicators that could be readily applied to any
comparable cluster over time. For the gross differences be-
tween regions, the strengths, weaknesses, opportunities
and threats (SWOT) and gap analyses were internally vali-
dated within the HealthTIES consortium. Moreover, as
medical and life sciences represent a sizable part of the re-
search and innovation system in each of the HealthTIES
regions, comparisons of our findings for medical and life
science clusters in the HealthTIES regions with the rank-
ings of their respective countries and administrative re-
gions across all sectors appear to indicate a degree of
external prima facie validity of the HealthTIES indicators
and indexes. In line with our findings that Life Science
Zürich outperforms other HealthTIES regions on the
greatest number of indicators, the European Innovation
Scoreboard shows that Switzerland is the overall
innovation leader in Europe, outperforming all EU mem-
ber states [4]. Similar to the Regional Innovation Score-
board (RIS) [5] ranking, the Oxford and Thames Valley
region was a high innovator and BioCat and Medical Delta
(only partial RIS data) were medium-high innovators. The
HealthTIES indexes indicate that Oxford and Thames Val-
ley performs slightly better than BioCat and Medical
Delta. Both the RIS and HealthTIES study revealed that
Debrecen is a low innovator.
Importantly, some of the differences between medical
and life science clusters in the HealthTIES regions couldbe addressed in the local regions (Additional file 1:
Figure S7). In an effort to create the ‘innovation space’
under the assumptions of the ‘triple helix’ model, the
initial regional and joint actions following the adoption
of the HealthTIES Innovation Indicators included the in-
stallation of formal ‘triple helix’ organisations (consisting
of academia, industry and government), professionalisa-
tion of the academic TTOs, investing in entrepreneur-
ship education, combined with incubator facilities and
international entrepreneurs in residence programmes
(Box 1). A set of joint actions could also lead to coupling
and collaboration of some of Europe’s most innovative
biotech regions such as combining business develop-
ment between regions, public–private R&D and entre-
preneurship education. Developing a more detailed
regional roadmap for further actions would require a
more integrated approach with ‘triple helix’ actors, com-
prehensive time-dependent data and prospective evalu-
ation following each initiative.
Best practice in bioincubation
Identifying and sharing best practice in bioincubation
provides an illustrative case of regional actions following
the adoption of the HealthTIES innovation indicators. A
bioincubator is a physical environment with labs and of-
fices where companies can start up, but also have access
to experienced entrepreneurs, venture capital vehicles,
skills training, mentoring and business services located
in close proximity to major universities, research institu-
tions, hospitals and life science companies. Most often,
bioincubators are new ‘triple helix’ organisational actors
Fig. 4 A comparative assessment of the innovation cycle using the HealthTIES Innovation index, 2010
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Box 1 Examples of initial regional and joint actions following the adoption of the HealthTIES innovation indicators
• BioCat: Improving the technology transfer offices (TTOs) transfer efficiency through roundtables with investors. Increase external
cooperation nationally and internationally through partnerships. Improve clinical trial organisation, in particular proposals on how to
improve clinical trial management and protocol turnaround.
• Észak-Alföld: Improve further public–private investment through Innova regional innovation engine. Student/researcher Mentoring
Programme to enhance forward intellectual property and innovation outputs. Improve the attraction and retention of foreign students
and leadership e.g. with new European Research Area strategic Chair.
• Medical Delta: Develop an innovation ‘Ambition’ programme with an integrated investment and TTO structure. Joint MD
professorships and joint education programme across the cluster. Set up an investment fund to support pre-competitive innovation. Cre-
ate large R&D facilities for public–private R&D ventures maximising utility of science parks. Study TTO best practice and propose a new
TTO format drawing on best practice.
• Oxford and Thames Valley: Address a major deficiency in the University’s ‘spin-out’ activity by developing an Oxford incubator. Study
best practice in biotech incubation, secure approval from all stakeholders, raise funding from public investment (Oxford City Deal) and
gain a planning permission. In Autumn 2015, building started on the Oxford BioEscalator – a new incubation facility to grow small spin-
off companies into mid-sized companies.
• Life Science Zürich: Address a major deficiency in translational research through a new ‘triple helix’ organisation for translational
medicine. Creation of a ripple helix organisation and action agenda for Life Science Zürich is in progress. Consider a potential
translational research centre and establish medical translational trials. Conduct a study on successful European Research Council laureate
candidates, followed by a proposal on how to improve leadership recruitment. Establish an entrepreneur in residence programme.
• Joint actions: HealthTIES partners developed a successful bid to the European Institute for Innovation and Technology (EIT) for a
Knowledge and Innovation Community in Health. Participate in joint education in innovation programmes using the EIT Health STELLAR
approach (Spark, Transform, Embrace, Lead, Leap, Amplify, Reward). Connect incubators as soft-landing places for exchange scientists, en-
trepreneurs and students (EIT Health).
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boundaries. In three HealthTIES regions (BioCat, Med-
ical Delta and Life Science Zürich), bioincubators proved
to be successful in stimulating innovation and economic
growth by creating new high-tech companies and jobs,
and therefore the Oxford regional team carried out site
visits and in-depth interviews to study best practice in
setting up and running bioincubators with a view to de-
veloping a bioincubator for Oxford and Thames Valley.
Major challenges in learning from international best
practice concerned the transferability of findings to the
intended setting. First, the functioning of bioincubators
appeared to be dependent on laws, taxes and other
country-specific institutions. Therefore, to increase the
transferability of best practice to the United Kingdom
context, in addition to five bioincubators in HealthTIES
regions, we studied a further six bioincubators in Eng-
land and Scotland. Second, the location and proximity of
a bioincubator to major universities, research institu-
tions, hospitals and life science companies emerged as
the most frequently cited strength of the bioincubators
studied. To capitalise on this strength, we studied
in-depth BioPartner Centre Leiden, which emulates the
proximity of the university and hospitals in Oxford bet-
ter than any other bioincubator studied. Third, funding
and sustainability in the first ten years of functioningemerged as the most frequently cited weakness of the
bioincubators studied. There was a high degree of vari-
ation in how different bioincubators raised the invest-
ment necessary to build and equip the actual physical
environment, attracted start-up companies, and gener-
ated revenue from multiple public and private sources
over time. As no uniform business model emerged, we
summarised a diverse range of best practice in setting
up and running bioincubators in a business model can-
vas (Additional file 2).
Discussion
This study reports the results and outcomes from the
European FP7 Regions of Knowledge HealthTIES pro-
ject. Specifically, our study provides tools for the meas-
urement and benchmarking of university–industry–
government innovation in selected European medical
and life science clusters. The general outcome is that the
HealthTIES indicators and indexes complement the
existing generic tools for measuring innovation perform-
ance across all sectors at the level of countries and large
administratively defined regions by focussing on actual
innovation clusters in one specific sector. The very na-
ture of this comparative process means that many indi-
cators that are potentially informative were subsequently
not used because of the lack of universal availability.
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cators that are based on what can be measured, rather
than on what should be measured. With respect to these
caveats, the HealthTIES indicators and indexes have
value, as they been co-developed and validated internally
within the HealthTIES consortium of regional partners
with representation from academia, government and in-
dustry, and appear to have a degree of external prima
facie validity.
In addition, the HealthTIES indicators and indexes
provided ample data for SWOT analysis, which in turn
formed the basis of our regional and joint action plans.
Our analysis shows that, although HealthTIES
innovation regions possess a strong knowledge base and
innovation infrastructure in the four mature clusters,
and a strong potential for development in the mentoring
cluster, they all significantly lag behind the world-leading
Boston cluster (Fig. 3). This is a reflection of Europe be-
ing outperformed by the global innovation leaders such
as South Korea, Canada, Australia, Japan and the United
States [4]. Although the EU still has a clear innovation
performance lead over many other countries globally,
this lead is declining rapidly and comes under threat
from countries such as China, whose innovation per-
formance growth is three times that of the EU [4].
HealthTIES had regional value, as we used the results
from the comparative assessment of the innovation cycle
to identify and share best practice and inform regional
and joint action plans to increase the competitiveness of
the HealthTIES regions. There was also a synergistic ef-
fect from involving regional stakeholders across aca-
demia, industry and government in gathering and
interpreting data. The HealthTIES project also raised
awareness and increased commitment to change among
the traditional ‘triple helix’ partners (academia, govern-
ment, and medical and life science industry), new part-
ners such as insurance companies and private investors,
and the general public.
With regard to the particular areas of the knowledge
and innovation capital, our study shows a major defi-
ciency in the area of medical chemistry across all five re-
gions. The lack of critical mass in this area in academia
and publicly funded research institutes may be compen-
sated by a larger volume of research in the pharmaceut-
ical industry. All of the regions appear to be dependent
on a steady drug development pipeline in the pharma-
ceutical industry, including vaccines and biological
agents. In view of the changes that are ongoing in the
pharmaceutical industry, these dependencies present a
potential threat to the continued high-level activity in
the HealthTIES clusters. For example, a major fall in rev-
enue for pharma is expected as the patent lifetime of
many drugs is coming to an end and they approach what
has been termed the ‘patent cliff ’ [53]. This fall inrevenue and the increasing costs of getting drugs
through Phase III, United States Food and Drug Admin-
istration and European Medicines Agency approval,
mean that many drug development programmes are
folding [54]. To counteract this threat in the context of
P4 (predictive, preventive, personalised, participatory)
medicine, academia and government across Europe may
need to play a more active role in basic research and
drug development in partnership with industry.
Limitations and future research
The HealthTIES indicators and indexes have a number
of limitations. First, our study was based on the assump-
tions of the ‘triple helix’ model to guide data collection,
analysis and actions. Testing the underlying assumptions
was beyond the scope of the study, as the ‘triple helix’
was regarded as a starting point. As a result, our analysis
and proposed actions focused on the dynamic interac-
tions within the ‘triple helix’ to generate a pragmatic,
measurable and effective evaluation of the parameters
influencing the innovation cycle. It is likely that this ap-
proach will have focused activity at the expense of other
sectors. For example, taking into the account the appar-
ent dependency of the HealthTIES regions on research
and drug development in the pharmaceutical industry,
incentivising R&D investment in the pharmaceutical in-
dustry through tax breaks could be either more or
equally advantageous to some of the actions we consid-
ered. We intend to repeat data collection and Health-
TIES innovation indicator analysis after implementation
of the initial regional and joint actions. The next steps in
evaluating the utility of the HealthTIES indicators and
subsequent actions should include wider evaluation of
the outcomes of the actions based on the assumptions of
the ‘triple helix’ model, as well as comparison of their
advantages and disadvantages with a range of possible
alternative actions to accelerate innovation.
Second, quantifying and measuring innovation is in-
herently challenging because, by definition, it is some-
thing novel and the settings within which it occurs are
multidimensional and in many ways unique. To ensure
comparability and quantitative measurability, our ap-
proach uses a variety of indirect innovation indicators
(e.g. research funding, publications, patents and invest-
ments) as well as quantitative direct innovation indica-
tors (e.g. new products on the market, new medicines,
big sales). An inherent limitation of such an approach is
that it does not focus on the qualitative characteristics of
the object of innovation, i.e. innovative products, ser-
vices and technologies. Future research may explore al-
ternative approaches focusing directly on the object of
innovation to investigate whether the new products, ser-
vices and technologies are incremental improvements or
disruptive innovations, whether they have a potential to
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whether they have occurred within or outside of the for-
mal medical and life science R&D sector.
Third, within the inherent limitations of the current
approach, there are considerable challenges in obtaining
complete, reliable and comparable datasets, particularly
for innovation system and output indicators. We were
unable to include in our analysis a number of indicators,
data for which were not available for all regions, or were
not comparable or quantifiable. Particularly, there may
be limitations to the reliability of some of the data col-
lected for the HealthTIES regions. For example, com-
panies complete their own entries in the BiotechGate
database, and so their entries may vary in terms of qual-
ity, consistency and reporting periods. Moreover, the
current version of the innovation indicators is based on
absolute rather than relative measurements and thus
does not take into consideration differences among
HealthTIES regions with regards to the size and quality
of various sociodemographic characteristics. Future re-
search may usefully develop a methodology to account
for such differences and to collect more complete, reli-
able and comparable data, for example, through compre-
hensive and cross-validated innovation surveys.
Fourth, external validation of the HealthTIES indica-
tors and indexes was beyond the scope of the current
project. Future research may usefully validate them in
other settings using both quantitative and qualitative val-
idation techniques. In particular, there may be a problem
in using some of the readily available indicators across
different settings. For example, the patients WAIT indi-
cator typically includes the innovations and new drugs
that have undergone market authorisation but are yet to
undergo Phase IV clinical trials to determine their
long-term effects on large populations, as well as health
technology assessment to determine their cost effective-
ness. Thus, some innovations and new drugs included in
this indicator in some settings may have adverse
long-term effects or may not be cost-effective. Our ex-
perience of conducting a workshop with a broad range
of experts including, among others, front-line clinicians
to build a consensus on the selection and feasibility of
innovation indicators suggest that member validation
and consensus research are likely to be effective means
to gather expert opinion and build a consensus on the
utility and feasibility of different indicators in the con-
text of different regions.
Finally, our study did not explore qualitative differ-
ences between the clusters with regard to the workforce,
business practices and laws, and how they support or
prevent innovation. Yet, our previous research in one of
the HealthTIES regions shows that innovation, entrepre-
neurship and collaboration culture varies between differ-
ent healthcare and research organisations and may affectboth health and economic outcomes [20, 55, 56]. More-
over, women remain under-represented in leadership
and management positions in European academic health
centres [57], which indicates that research systems may
not support the best science or fail to address topics that
benefit women and men equitably [58]. Future research
may usefully explore qualitative differences between or-
ganisations, sectors and regions using theory-building
research designs to draw generalisations beyond the
current sample of medical and life science clusters.
Conclusion
Important sectors of the economy, such as medical and
life sciences, increasingly revolve around a ‘triple helix’
of university–industry–government relations at both na-
tional and regional levels. In light of growing inter-
dependencies between previously arms-length actors, it
is vital for research and innovation stakeholders and
policy-makers to have access to tools for measuring,
monitoring and comparing ‘triple helix’ dynamics in key
sectors. The HealthTIES indicators and indexes provide
useful practical tools for the measurement and bench-
marking of university–industry–government innovation
in European medical and life science clusters. They have
been developed and validated internally within the
HealthTIES consortium and display a degree of external
prima facie validity. The results from the comparative
assessment of the innovation cycle have been used to
identify and share best practice and inform regional and
joint action plans to strengthen the competitiveness of
the HealthTIES regions. Potentially, the tools and ac-
companying analyses can be used beyond the Health-
TIES consortium to inform other regional governments,
researchers and, possibly, large companies searching for
their next location, analyse and benchmark ‘triple helix’
dynamics within their own networks over time, and to
develop integrated public–private and cross-regional re-
search and innovation strategies in Europe and beyond.
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